Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print April 9, 2008, doi:10.1212/01.wnl.0000312381.29287.ff)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000312381.29287.ffv1
70/21/1980    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Eberling, J. L.
Right arrow Articles by Aminoff, M. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eberling, J. L.
Right arrow Articles by Aminoff, M. J.
Received October 11, 2007
Accepted February 14, 2008

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

J. L. Eberling PhD*, W. J. Jagust MD, C. W. Christine MD, P. Starr MD, P. Larson MD, K. S. Bankiewicz MD, PhD, and M. J. Aminoff MD, DSc

From the Department of Molecular Imaging and Neuroscience (J.L.E., W.J.J.), Lawrence Berkeley National Laboratory, Berkeley, CA; Department of Neurology (J.L.E.), University of California, Davis, CA; University of California (W.J.J.), Berkeley, CA; and Departments of Neurology (C.W.C., M.J.A.), and Neurological Surgery (P.S., P.L., K.S.B.), University of California, San Francisco, CA.


* To whom correspondence should be addressed. E-mail: jleberling{at}lbl.gov.

Background: In a primate model of Parkinson disease (PD), intrastriatal infusion of an adeno-associated viral (AAV) vector containing the human aromatic L-amino acid decarboxylase (hAADC) gene results in robust gene expression. After gene transfer, low doses of systemically administered L-dopa are converted to dopamine in the transduced striatal neurons, resulting in behavioral improvement without the side effects typically associated with higher doses of L-dopa. These studies led to the initiation of a phase I safety trial. Here we report the findings for the first cohort of five patients.

Methods: Patients with moderate to advanced PD received bilateral infusion of a low dose of the AAV-hAADC vector into the putamen. PET scans using the AADC tracer, 6-[18F]fluoro-L-m-tyrosine (FMT), were performed at baseline and at 1 and 6 months after infusion as an in vivo measure of gene expression.

Results: PET results showed an average 30% increase in FMT uptake (Kic) in the putamen after gene transfer. Preliminary analysis of clinical data indicates a modest improvement, but absence of a control and the nonblinded analyses make interpretation difficult.

Conclusions: Thus far, this gene therapy approach has been well tolerated and shows PET evidence of sustained gene expression. These initial findings demonstrate the safety of the therapy; higher doses of adeno-associated viral vector containing the human aromatic L-amino acid decarboxylase gene in the next cohort of patients may further increase dopamine production in the putamen and provide more profound clinical benefit.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.